Type 2 Diabetes Clinical Trial
— HAPPYOfficial title:
Harnessing Human Potential and Improving Health Span in Women and Their Children: a Randomized Controlled Trial and Follow-up (HAPPY STUDY)
Women with Gestational Diabetes Mellitus (GDM) are 12-times more likely to develop Type 2 Diabetes (T2D) 4-6 years after delivery than women without GDM. There has been evidence that lifestyle modifications such as physical activity (PA), dietary intake, sleep, and stress management can prevent or delay type 2 diabetes (T2D). The purpose of this study is to assess the efficacy of a holistic lifestyle digital health intervention with post-GDM women in large community settings in Singapore. The study consists of a 1-year randomized controlled trial (RCT) with 3 years follow-up. Women who are eligible for the study will be randomized to either Group 1 (Intervention) or Group 2 (Control) at baseline. Both groups will be followed in years 2-4. Women from both groups will be provided with an Oura ring for tracking physical activity, sleep, and heart rate variability (a proxy for stress), and the "HAPPY app," which will provide health promotion information about physical activity, diet, sleep, and mental wellbeing, as well as display the information collected (such as body mass index, blood pressure, and OGTT results). The active group will receive the "LVL UP app" a smartphone-based chatbot-delivered intervention, designed to provide personalized recommendations through multiple digital coaching sessions aimed at improving health literacy and practicing healthy lifestyles to prevent Type 2 diabetes and common mental disorders (i.e., anxiety, depression).
Status | Recruiting |
Enrollment | 400 |
Est. completion date | December 3, 2028 |
Est. primary completion date | December 3, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 21 Years to 45 Years |
Eligibility | Inclusion Criteria: 1. Female, age: 21 - 45 years 2. Had a history of GDM (at least 1 year and not more than 10 years) 3. Chinese, Malay or Indian ethnic groups 4. Body mass index (at least 18.5 kg/m2 and not more than 35 kg/m2) 5. Not planning to conceive in the next one year 6. Not performing exclusive breastfeeding during study period 7. Own a smartphone compatible with the study mobile Apps 8. Proficient in English language 9. Plan to stay in Singapore for the next 4 years 10. Willing to comply to study protocol 11. Able to provide a written informed consent Exclusion Criteria: 1. Current or previous diagnosis of diabetes (Type 1 or 2), except GDM 2. Currently pregnant 3. Given birth within the last 12 weeks 4. Severely limited mobility (e.g., wheelchair bound, require long-term walking aid, etc.) 5. Diagnosed with malnutrition or eating disorder 6. Diagnosed with cancers, unstable heart diseases, severe kidney diseases, severe liver diseases 7. Diagnosed with severe insomnia, unstable mental conditions, dementia, or cognitive impairment 8. Experienced alcohol or drug abuse 9. Currently having medications known to influence glucose metabolism (e.g. peroral corticosteroids) 10. Currently participating in concurrent clinical trial or lifestyle intervention study |
Country | Name | City | State |
---|---|---|---|
Singapore | Singapore Institute for Clinical Sciences (SICS) | Singapore |
Lead Sponsor | Collaborator |
---|---|
Singapore Institute for Clinical Sciences |
Singapore,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cognitive emotion regulation strategies | CERQ: Cognitive Emotion Regulation Questionnaire | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Sleep wake up | MEQ:The morningness-eveningness questionnaire | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Happiness | SHS: Subjective Happiness Scale | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Health Literacy | HLQ: Health Literacy Questionnaire | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Stress | PSS-4: Perceived Stress Scale 4 | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Mental Wellbeing | WHO-5 wellbeing Index | Baseline, Week 26 (Midpoint Visit), Year1 | |
Other | Infant sleep | BISQ-R-SF: Brief infant sleep questionnaire is on parent-reported toddler (0-3 years) sleep over prior 1 week. | Baseline, year 1 | |
Other | Child and Mother Interaction | StimQ-toddler (for age 1-3 years) / StimQ-pre-school (for age 4-5 years) is designed to find out the different types of toys and games that mothers have for child in the home, and the kinds of activities that mother and child do together. | 12 months (Year 1 visit) | |
Other | Child's Sleep Habits | CSHQ: Child's Sleep Habits Questionnaire (for age 4-5 years) assesses the frequency of children behaviors associated with common pediatric sleep difficulties. | Baseline, year 1 | |
Primary | Glucose Tolerance Changes | 2-hr 75g Oral Glucose Tolerance Test (OGTT) | Changes in glucose over four years, including: Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Anthropometric Measurements | Participants will be measured for their height in feet and weight in kilograms. Weight and height will be combined to report BMI in kg/m^2. | Baseline, Week 26/27 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Blood pressure (BP) | Blood pressure will be measured using an automated blood pressure monitor. | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Biosample Collection (Fasting blood) | Fasting blood draw will be analyzed for HbA1c & fasting blood glucose | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Biosample Collection (Saliva) | Saliva collected using Salivette® kit (cortisol) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Biosample Collection (Buccal swab) | Buccal swab collected using Isohelix kit (DNA profiling) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Biosample Collection (Stool) | Stool collected via OMNIgene®•GUT OM-200 (Gut microbiota) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Bioelectrical Impedance Analysis (BIA) | BIA is a non-invasive technology that can accurately measure a person's total body water, extracellular and intracellular fluid volumes. | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Depression | Beck Depression Inventory II (BDI-II) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Anxiety | The State-Trait Anxiety Inventory (STAI) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Health Status | The Short Form (36) Health Survey (SF-36) | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Sleep | PSQI: The Pittsburgh Sleep Quality Index (PSQI | Baseline, Week 26 (Midpoint Visit), Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Lifestyle | e-Diary (Qualtrics survey system) self-report lifestyle | Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) | |
Secondary | Social-emotional development (Children) | ASQ:-3: Ages and stages questionnaire: social-emotional development screening tool is used to assess children's (for age 2 month - 60 months) self-regulation, communication, autonomy, compliance, adaptive functioning, affect, and interaction with people. | Baseline, Year1, Year 2 (Follow-up 1), Year 3(Follow-up 2), Year 4(Follow-up 3) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |